Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nifurtimox→

Nifurtimox Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
23256-30-6
Molecular formula
C10H13N3O5S
Molecular weight
287.29 g/mol
Drug class
Nitrofuran antiprotozoal agenttrypanocidal drug
Mechanism of action
Undergoes nitroreductase-mediated reduction in Trypanosoma cruzi, generating reactive intermediates and oxidative stress that damage parasite DNA, proteins and other cellular components.
Indications / reported uses
  • Treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi in paediatric and eligible adult patients; the specific product label determines age, weight and combination requirements

Sources: US DailyMed — LAMPIT (nifurtimox) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nifurtimox Environmental Risk Assessment (ERA) (the Nifurtimox ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.